Sol-Gel Technologies (NASDAQ:SLGL) Upgraded to Buy at Wall Street Zen

Key Points

• Sol-Gel Technologies has been upgraded to a "buy" rating by Wall Street Zen, indicating increased investor confidence in the company's prospects.
• The company's stock price increased by 2.3%, reflecting positive market reactions following the upgrade.
• In its latest earnings report, Sol-Gel Technologies posted an impressive $4.17 EPS, significantly beating analysts' expectations of a loss.

Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a "buy" rating in a research note issued to investors on Saturday.

Sol-Gel Technologies Stock Up 2.3%

Shares of SLGL stock opened at $24.63 on Friday. The company has a 50 day moving average price of $16.04 and a 200-day moving average price of $9.79. Sol-Gel Technologies has a 52 week low of $4.01 and a 52 week high of $30.00. The firm has a market capitalization of $68.70 million, a PE ratio of -20.02 and a beta of 1.26.

Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) last announced its quarterly earnings results on Friday, August 15th. The company reported $4.17 EPS for the quarter, topping analysts' consensus estimates of ($0.67) by $4.84. Sol-Gel Technologies had a negative net margin of 14.25% and a negative return on equity of 11.80%. The firm had revenue of $17.26 million during the quarter, compared to analyst estimates of $2.86 million. Analysts anticipate that Sol-Gel Technologies will post -0.28 earnings per share for the current year.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.